Why Axsome Therapeutics Stock Is Soaring Today
Shares of Axsome Therapeutics ( AXSM 4.36%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was up as much as 5.6% earlier in the day. The jump comes as the S&P 500 ( ^GSPC 0.02%) lost 0.3% and the Nasdaq Composite ( ^IXIC -0.06%) lost 0.3% on the day.
Axsome Therapeutics price target raised to $160 from $140 at Wells Fargo
Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $140 and keeps an Overweight rating on the shares. The
Leerink Partners Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $150.00
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective boosted by analysts at Leerink Partners from $110.00 to $150.00 in a research report issued on Monday,Benzinga reports. The firm presently has an “outperform” rating on the stock.
Why Axsome Therapeutics Stock Is Skyrocketing Today
Shares of Axsome Therapeutics (NASDAQ: AXSM) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, gaining as much as 25% earlier in the day. The move up comes as the S&P 500 (SNPINDEX: ^GSPC) gained 0.
Axsome Therapeutics price target raised to $167 from $143 at BofA
BofA analyst Jason Gerberry raised the firm’s price target on Axsome Therapeutics (AXSM) to $167 from $143 and keeps a Buy rating on the shares
Mizuho raises Axsome stock target to $195, maintains Outperform
Securities exhibited confidence in Axsome Therapeutics (NASDAQ:AXSM) by increasing the company's price target from $137.00 to $195.00. The firm has maintained an Outperform rating on the stock. This revision comes in the wake of a patent settlement with Teva Pharmaceuticals,
UBS raises Axsome Therapeutics stock price target to $133
UBS analysts increased the price target on Axsome Therapeutics (NASDAQ:AXSM) shares to $133.00, up from the previous $105.00, while maintaining a Buy rating on the stock. The company, currently valued at $6.
Why Axsome Therapeutics (AXSM) Is Advancing Today
Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from ...
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.
FiercePharma2d
Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Fintel on MSN1d
Deutsche Bank Initiates Coverage of Axsome Therapeutics (AXSM) with Buy Recommendation
Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Buy ...
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The ...
Axsome settles Auvelity patent litigation with Teva
Axsome Therapeutics (AXSM) stock rallied 15% on news the company has settled patent litigation with Teva (TEVA) over a ...
Zacks.com on MSN2d
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?
Axsome (AXSM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...